RegenxBio Inc. and the University of Pennsylvania convinced the Federal Circuit to reinstate a gene-therapy patent a district judge had invalidated as covering natural phenomena, reviving their infringement suit against
RegenxBio, a licensee of Penn’s patent, has said it would seek more than $900 million in damages if it ultimately proves Sarepta infringed US Patent No. 10,526,617 in the dispute over gene therapies for Duchenne muscular dystrophy.
The US Court of Appeals for the Federal Circuit, in a precedential opinion issued Friday, reversed a summary judgment ruling that the ‘617 patent is ineligible under Section 101 of ...